(1974). FM: Malignant reticuloendothelial disease involving the ovary as a primary manifestation: a series of 19 lymphomas and 1 granulocytic sarcoma. Cancer
(2003). Hollomby DJ, House AA: Epstein-Barr virus seronegativity is a risk factor for late-onset post-transplant lymphoproliferative disorder in adult renal allograft recipients. Transplantation
(1993). LJ: Malignant lymphomas involving the ovary. A clinicopathologic analysis of 39 cases.
(1998). Malignant lymphoma of the ovary: report of a case successfully managed with surgery and chemotherapy. Gynecol Oncol
(1988). MH: Malignant lymphoma presenting as an ovarian tumour: a clinicopathological analysis of 34 cases.
(2005). Rituximab therapy is effective for post-transplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial. Cancer
(2007). Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab. Transplantation
(2001). Stadtmauer EA: Reduction in immunosuppression as initial therapy for post-transplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation
(1999). Starzl TE: Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression. Transplantation
(2006). Stehmen-Breen C: Risk of lymphoma after renal transplantation varies with time: an analysis of the United States Renal Data System. Transplantation